Claims for Patent: 8,492,406

Summary for Patent: 8,492,406

Title:	Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	12/755,875
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,492,406
Patent Claims:	1. A method of treating follicular lymphoma, which comprises administering to a patient having follicular lymphoma about 5 to about 50 mg per day of a compound of the formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 2. The method of claim 1, wherein the follicular lymphoma is low grade follicular lymphoma, refractory follicular lymphoma, or relapsed follicular lymphoma. 3. The method of claim 1, wherein the compound is ##STR00010## 4. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 5. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 6. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer. 7. The method of claim 6, wherein the stereoisomer is an enantiomerically pure R isomer. 8. The method of claim 6, wherein the stereoisomer is an enantiomerically pure S isomer. 9. The method of claim 1, which further comprises administering a therapeutically effective amount of a second active agent. 10. The method of claim 9, wherein the second active agent is hematopoietic growth factor, a cytokine, or an anti-cancer agent. 11. The method of claim 9, wherein the second active agent is rituximab, vinblastine, fludarabine, cyclophosphamide, vincristine, doxorubicin, prednisone, or a combination thereof. 12. The method of claim 9, wherein the second active agent is rituximab. 13. The method of claim 9, wherein the second active agent is vinblastine. 14. The method of claim 9, wherein the second active agent is fludarabine. 15. The method of claim 1, which further comprises administering radiation therapy, hormonal therapy, biological therapy or immunotherapy. 16. The method of claim 1, wherein the follicular lymphoma is relapsed, refractory or resistant to conventional therapy. 17. The method of claim 1, wherein the compound is administered orally. 18. The method of claim 17, wherein the compound is administered in the form of a capsule or tablet. 19. The method of claim 1, wherein the compound is administered in an amount of from about 10 to about 25 mg per day. 20. The method of claim 1, wherein the compound is administered in an amount of about 5, 10, 20, 25, 30, or 50 mg per day. 21. The method of claim 1, wherein the compound is administered in an amount of from about 5 mg per day to about 25 mg per day. 22. The method of claim 1, wherein the compound is administered in an amount of about 25 mg per day. 23. The method of claim 1, wherein the compound is administered cyclically. 24. The method of claim 23, wherein one cycle comprises four to six weeks. 25. The method of claim 23, wherein one cycle comprises the administration of the compound for 21 days followed by seven days rest. 26. The method of claim 24, which comprises one to twenty-four cycles. 27. The method of claim 1, wherein the compound is administered in an amount of from about 5 to about 25 mg per day for days 1-21 every 28 days. 28. The method of claim 23, wherein the compound is administered in an amount of about 25 mg per day for 21 days followed by seven days rest in a 28 day cycle. 29. The method of claim 1, wherein the compound is administered in an amount of about 5 mg per day. 30. The method of claim 1, wherein the compound is administered in an amount of 10 mg per day. 31. The method of claim 1, wherein the compound is administered in an amount of 15 mg per day. 32. The method of claim 1, wherein the compound is administered in a capsule of 5 mg, 10 mg, 15 mg, 20 mg or 25 mg. 33. The method of claim 18, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.